News

Harpoon Therapeutics' TriTAC molecules are half-life extended and designed to simultaneously bind to cancer cells and T-cells, triggering those T-cells to attack the targeted cancer cells. These molecules

The late-stage study, dubbed MURANO, demonstrated that Venclexta/Venclyxto, an oral B-cell lymphoma-2 (BCL-2) inhibitor in combination with MabThera/Rituxan cut down the risk of disease progression or death by 83%

Alzheimer’s Clinical Trial Consortium (ACTC), which covers 35 sites across the US, will engage in the development of new and effective ways to treat Alzheimer’s related disorders. The

In connection with the investment, James Peyer, Managing Partner of Apollo Ventures, has joined Aeonian's Board of Directors. Aeonian is an early-stage company engaged in the discovery and

The deal will provide Fosun Pharma with the exclusive rights to develop and commercialize Ardelyx's lead product, tenapanor, in China for the treatment of patients with irritable bowel syndrome

The approval from the drug regulator covers adults and pediatric patients aged 3 years and older with type 1 diabetes mellitus and adults with type 2 diabetes mellitus.

The study has demonstrated enhanced PFS in patients treated with talazoparib compared against patients who received physician’s choice standard of care chemotherapy. Talazoparib is an investigational, oral and

NICE recommends lenvatinib, also known as kisplyx, be given in conjunction with another drug called everolimus. This drug-duo is recommended as an option for people who have previously

AP-002 is a nasally inhaled surfactant based on a combination of Lyomark's Alveofact® (bovine lung surfactant) and Aerogen's next generation "PDAP™" delivery technology.  The partners expect AP-002 to